BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

about

Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma.

P2860

Q48540669-6477348D-0C3D-434D-A7DD-E405F69A49DD

P2860

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q39350678

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@en

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@nl

type

Item

label

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@en

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@nl

prefLabel

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@en

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@nl

P1476

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

@en

P2093

Daniel Olszta

http://www.w3.org/2001/XMLSchema#string

Jill Rhodes

http://www.w3.org/2001/XMLSchema#string

Michael Vozniak

http://www.w3.org/2001/XMLSchema#string

Nicholas Forcello

http://www.w3.org/2001/XMLSchema#string

Sandra Cuellar

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Tyrosine kinase inhibitors and pregnancy.

Cytochrome P-450 3A4: regulation and role in drug metabolism.

Drug-induced QT interval prolongation: mechanisms and clinical management

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

P304

1078155217710553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1177/1078155217710553

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28580869

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

mechanism of action

proto-oncogene proteins

neoplasm proteins

mutant proteins

chronic myeloid leukemia

Anzim

P932

6094551

http://www.w3.org/2001/XMLSchema#string

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

about

P2860

P2860

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P5008

P577

P698

P921

P932